Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.36 |
| ▸ | FBP1 | P09467 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 5/20 | 0.32 |
| ▸ | NPC1 | O15118 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10893459 | 0.74 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GJAK2MAP4K4RET | |
| SCHEMBL10888852 | 0.74 | ALDH1A1 (0.31) | RAB9ANPC1TP53ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL10891371 | 0.73 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GJAK2MAP4K4RET | |
| Evandamine SCHEMBL6009808 | 0.71 | APOBEC3A (0.42) | APOBEC3AAPOBEC3GJAK2MAP4K4RET | |
| SCHEMBL13387645 | 0.66 | PDK1 (0.36) | APOBEC3AAPOBEC3GJAK2MAP4K4RET | |
| SCHEMBL10890832 | 0.65 | NPC1 (0.37) | APOBEC3AAPOBEC3GPDK1FBP1TSHR | |
| SCHEMBL16695138 | 0.64 | SMN1; SMN2 (0.53) | APOBEC3AAPOBEC3GJAK2MAP4K4RET | |
| Hydrochloric Acid SCHEMBL10891755 | 0.64 | NPC1 (0.36) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A | |
| SCHEMBL10893914 | 0.63 | ABL1 (0.44) | TSHRRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL558522 | 0.63 | APOBEC3A (0.95) | APOBEC3AAPOBEC3GPDK1FBP1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320697-A1 | Methods For Bone Treatment By Modulating An Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. | 2015-11-12 | — | — | US | claimed |
| EP-1947942-B1 | METHODS FOR BONE TREATMENT BY MODULATING AN ARACHIDONIC ACID METABOLIC OR SIGNALING PATHWAY | ACCELALOX INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8980851-B2 | Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway | ACCELALOX, INC. (US) | 2015-03-17 | — | — | US | claimed |
| WO-2014031586-A2 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20110124717-A1 | Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-7829535-B2 | for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. | ACCELALOX, INC. (US) | 2010-11-09 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20080280826-A1 | for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. | ACCELALOX, INC. (US) | 2008-11-13 | — | — | US | claimed |
| EP-1385505-B1 | ACNE TREATMENT WITH LIPOOXIGENASE INHIBITORS | ZOUBOULIS CHRISTOS (DE) | 2006-07-05 | — | — | EP | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| US-6136839-A | USING A SULFONE OR SULFOAMIDE BENZENE COMPOUND | G. D. SEARLE & CO. (US) | 2000-10-24 | — | — | US | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | APOBEC3A 2316/4885APOBEC3G 2205/4885JAK2 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.